Clinical Trials
- Children's Health, Diseases of the Respiratory Systems
Efficacy and Safety of OPN-375 186 ug Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps
- Ages12 years - 17 years
- GenderBoth
- Date04/29/2019
- Asthma
PrecISE: Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network
- Ages18 years and older
- GenderBoth
- Date08/21/2020
- Head and Neck Cancers
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Ages18 years and older
- GenderBoth
- Date06/23/2015
- COVID-19 Inpatient, COVID-19 Outpatient
Long Covid: Understanding Immune, Symptom, and Treatment Experiences Nationwide (LISTEN Study)
- Ages18 years and older
- GenderBoth
- Date04/01/2022
- Tobacco Addiction
The interaction of flavor with nicotine form in adult smokers
- Ages21 years and older
- GenderBoth
- Date01/16/2020
- Addictive Behavior, Mental Health & Behavioral Research, Tobacco Addiction
Switching to Potential Reduced Exposure Products in Adult Smokers (JUUL)
- Ages21 years - 77 years
- GenderBoth
- Date12/10/2018
- Head and Neck Cancers
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
- Date01/14/2022
- Head and Neck Cancers
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
- Ages18 years and older
- GenderBoth
- Date04/03/2017
- Orthopaedics, Muscle & Bone
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
- Ages40 years - 80 years
- GenderBoth
- Date07/01/2020
- Head and Neck Cancers
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Ages18 years and older
- GenderBoth
- Date05/18/2022